8-K: KalVista's EKTERLY Gains Momentum, Funds Through Profit

KalVista Pharmaceuticals reports strong initial US sales for EKTERLY, expands globally, and secures funding to reach profitability.

Summary

• Recognized $13.7 million in net product revenue for EKTERLY in the three months ended September 30, 2025, following its US commercial launch on July 7, 2025.
• Received 937 patient start forms and activated 423 unique prescribers for EKTERLY through October 31, 2025.
• Launched EKTERLY in Germany in October, with initial orders indicating encouraging demand.
• Secured regulatory approvals for EKTERLY in the European Union (EC), Switzerland, and Australia in September and October, adding to its existing US and UK approvals.
• Reported cash, cash equivalents, and marketable securities of approximately $309.2 million as of September 30, 2025, which, combined with projected EKTERLY revenues, is expected to fund the company through profitability.
• Research and development expenses decreased to $12.0 million for the quarter, down from $18.7 million in the prior year period, primarily due to reduced clinical trial expenses.
• Selling, general and administrative expenses increased to $46.5 million for the quarter, up from $24.8 million in the prior year period, mainly due to EKTERLY commercialization efforts.
• Reported a net loss of $49.5 million, or $0.92 per share, for the quarter ended September 30, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong initial commercial success of EKTERLY, significant global expansion, and a robust cash position expected to fund the company through profitability. However, this is tempered by increased operating losses driven by high commercialization expenses, which are typical for a product launch but still represent a current negative.

Positives

• EKTERLY's US launch is gaining strong momentum, generating $13.7 million in net product revenue in its first partial quarter.
• Rapid adoption of EKTERLY is evident with 937 patient start forms and 423 unique prescribers activated through October.
• Successful international expansion with EKTERLY launches in Germany and approvals in the EU, Switzerland, and Australia, making it a truly global product.
• The company holds $309.2 million in cash, cash equivalents, and marketable securities, which is anticipated to fund operations through profitability.
• Reduced research and development expenses, reflecting a shift towards commercialization post-approval.

Negatives

• Selling, general and administrative expenses significantly increased to $46.5 million due to commercialization efforts for EKTERLY.
• Reported a net loss of $49.5 million for the quarter, an increase from $39.1 million in the prior year period.
• Operating loss increased to $46.1 million from $43.5 million in the prior year period.

Risks

• The success of efforts to commercialize EKTERLY, including achieving projected revenues from sales.
• Ability to successfully obtain additional foreign regulatory approvals for sebetralstat.
• Uncertainties regarding the safety and efficacy of sebetralstat and other product candidates.
• The timing of clinical trials and their results, including the KONFIDENT-S and KONFIDENT-KID trials.
• Ability to commence clinical studies or complete ongoing clinical studies.
• The future progress and potential success of the oral Factor XIIa program.

Future Outlook

The company anticipates that its cash, cash equivalents, and marketable securities of approximately $309.2 million as of September 30, 2025, combined with projected revenues from EKTERLY sales, will fund the company through profitability. KalVista plans to continue advancing its global launch strategy for EKTERLY, with ongoing studies exploring its use in pediatric patients (KONFIDENT-KID) and multiple regulatory applications under review in key global markets, aiming for EKTERLY to become a foundational therapy for HAE management worldwide.

Management Comments

• "The US launch of EKTERLY is progressing with significant momentum, driven by strong early demand and rapid adoption among physicians and people living with HAE."
• "We continue to see encouraging trends, with both new patient starts and repeat prescriptions increasing consistently, reflecting sustained uptake and confidence in the clinical value of EKTERLY as the first and only oral on-demand treatment for hereditary angioedema."
• "We also recently launched EKTERLY in Germany, with very positive initial demand. And with our most recent approval in Australia, we now hold five regulatory approvals and are on our way to making EKTERLY a truly global product."
• "With the successful closing of our recent $144 million convertible note offering, we have the financial resources to continue advancing our global launch strategy and building long-term growth."

Industry Context

EKTERLY's emergence as the first and only oral on-demand treatment for hereditary angioedema (HAE) represents a significant advancement in the rare disease market. This positions KalVista to potentially disrupt the existing HAE treatment landscape, which has historically relied on injectable therapies. The rapid adoption and global expansion efforts indicate a strong market need for convenient, oral alternatives, aligning with broader industry trends towards patient-centric and less invasive treatment options for chronic conditions.

Comparison to Industry Standards

• EKTERLY is positioned as the first and only oral on-demand treatment for HAE, which is a significant differentiator compared to existing injectable on-demand treatments like icatibant, pdC1INH, and rhC1INH.
• Interim results from the KONFIDENT-KID trial showed a median time to dosing of 30 minutes and a median time to symptom relief of 1.5 hours for pediatric patients, demonstrating rapid action for an oral therapy.
• Patient satisfaction data from KONFIDENT-S, where 84% of attacks treated with sebetralstat were rated as satisfied (median score of 2, 'very satisfied') by patients switching from injectables, suggests a high level of preference for the oral option over traditional methods.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant long-term value creation due to strong EKTERLY launch and global expansion, but also near-term dilution risk from the convertible note offering and ongoing losses.
• Patients (HAE): Access to the first and only oral on-demand treatment, offering a more convenient and potentially life-changing therapy option.
• Employees: Expansion of the management team (COO, CPO) indicates growth and investment in human capital.
• Investment Professionals: Provides critical data on the commercial trajectory of EKTERLY and the company's financial runway.

Next Steps

• Host a conference call and webcast on November 11, 2025, to discuss the financial results and operational update.
• Continue advancing the global launch strategy for EKTERLY in approved markets.
• Progress ongoing clinical studies, including KONFIDENT-KID for pediatric patients aged 2-11.
• Pursue multiple regulatory applications for EKTERLY in additional key global markets.

Key Dates

Recommendation

The strong initial commercial performance of EKTERLY, evidenced by $13.7 million in net product revenue and rapid patient/prescriber adoption, signals a highly successful launch for a first-in-class oral therapy. Global expansion with approvals and launches in key markets like the EU, Switzerland, Germany, and Australia further solidifies its market potential. While the company is currently operating at a loss due to significant commercialization investments, the substantial cash reserves of $309.2 million, bolstered by a recent convertible note offering, provide a clear runway to profitability. This robust financial position, combined with the strong market reception for EKTERLY, suggests significant growth potential and makes KalVista an attractive investment for long-term growth-oriented investors.

Keywords

HAE, EKTERLY, sebetralstat, hereditary angioedema, oral treatment, pharmaceuticals, rare disease, commercial launch, financial results, biotechnology